Stock Events

Stock Events

Haemato

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Dividends

0%Dividend Yield

Jul 2019

€3.00

Jul 2018

€3.00

Jun 2017

€3.00

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Financials

2.75%Profit Margin

Profitable

2018

2019

2020

2021

2022

2023

281.51MRevenue

7.74MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Novartis is a global healthcare company that operates in the pharmaceuticals sector, directly competing with Haemato in the development and marketing of medical products.

Pfizer is a multinational pharmaceutical corporation that competes with Haemato in the pharmaceuticals market, particularly in the areas of research, development, and distribution of drugs.

Merck & Co., Inc. is a leading global biopharmaceutical company that competes with Haemato in the discovery, development, and commercialization of medicines and vaccines.

Johnson & Johnson

Johnson & Johnson is a comprehensive healthcare company that has a strong presence in the pharmaceuticals sector, making it a competitor to Haemato in various therapeutic areas.

GlaxoSmithKline is a global healthcare company that engages in the creation and distribution of pharmaceuticals, vaccines, and consumer healthcare products, competing with Haemato.

AbbVie is a biopharmaceutical company that develops and markets therapies, directly competing with Haemato in the pharmaceuticals and healthcare market.

Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines, competing with Haemato in several therapeutic areas.

Sanofi is a global life sciences company that offers a wide range of pharmaceutical products, directly competing with Haemato in the healthcare and pharmaceutical sectors.

Roche Holding AG is a pioneer in healthcare, focusing on pharmaceuticals and diagnostics, and competes with Haemato in the development and marketing of medical solutions.

AstraZeneca is a global, science-led biopharmaceutical business that competes with Haemato in the discovery and development of prescription medicines.

About

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European imported drugs and medical products; and manufactures and distributes its own generic medicinal products. It provides pharmaceuticals in the areas of oncology, HIV/AIDS, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic treatments. The company also develops and markets medical devices and medical technology products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors, clinics, medical laboratories, and hospitals. The company was founded in 1993 and is headquartered in Schönefeld, Germany.

Show More

CEO

Employees

147

Country

United Kingdom

ISIN

DE0006190705

WKN

000A289VV

Listings

0 Comments

Share your thoughts

FAQs

What is Haemato stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Haemato stocks are traded under the ticker HAE.MU.

What is Haemato revenue for the last year?▼

Haemato revenue for the last year amounts to 281.51M EUR.

What is Haemato net income for the last year?▼

HAE.MU net income for the last year is 7.74M EUR.

Does Haemato pay dividends?▼

Yes, HAE.MU dividends are paid annual. The last dividend per share was 3 . As of today, Dividend Yield (FWD)% is 0%.

How many employees does Haemato have?▼

As of October 8, 2026, the company has 147 employees.

In which sector is Haemato located?▼

Haemato operates in the Energy sector.

When did Haemato complete a stock split?▼

The last stock split for Haemato was on September 2, 2020 with a ratio of 1:10.